Intercept Pharmaceuticals (ICPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 88,789 | 83,718 | 67,958 | 77,219 | 77,588 |
| Cost of Goods | 197 | 185 | 222 | 28 | 424 |
| Gross Profit | 88,592 | 83,533 | 67,736 | 77,191 | 77,164 |
| Operating Expenses | 93,408 | 90,837 | 99,590 | 95,500 | 87,732 |
| Operating Income | -4,619 | -7,119 | -31,632 | -18,281 | -10,144 |
| Interest Expense | 1,802 | 2,812 | 2,809 | 2,806 | 5,237 |
| Other Income | 3,661 | 4,105 | 2,560 | 4,072 | -88,706 |
| Pre-tax Income | -2,760 | -5,826 | -31,881 | -17,015 | -104,087 |
| Net Income Continuous | -2,760 | -5,826 | -31,881 | -17,015 | -104,087 |
| Net Income Discontinuous | -30 | -36 | -254 | -3,810 | 371,540 |
| Net Income | $-2,790 | $-5,862 | $-32,135 | $-20,825 | $267,453 |
| EPS Basic Total Ops | -0.07 | -0.14 | -0.77 | -0.41 | 7.80 |
| EPS Basic Continuous Ops | -0.07 | -0.14 | -0.77 | -0.32 | -3.04 |
| EPS Basic Discontinuous Ops | 0.00 | 0.00 | -0.01 | -0.08 | 10.83 |
| EPS Diluted Total Ops | -0.07 | -0.14 | -0.77 | -0.41 | 7.80 |
| EPS Diluted Continuous Ops | -0.07 | -0.14 | -0.77 | -0.32 | -3.04 |
| EPS Diluted Discontinuous Ops | 0.00 | 0.00 | -0.01 | -0.08 | 10.83 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.14 | -0.77 | -0.42 | -3.04 |
| EBITDA(a) | $-6,146 | $-8,979 | $-33,140 | $-19,162 | $-9,671 |